Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572062 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT03572062 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 317 participants.
The verdict
NCT03572062, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with seasonal inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine administered12 months after the initial dose. In addition the study will evaluate a 2-dose regimen administered 2 months apart to 62 subjects.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Formulation A
- BIOLOGICAL Formulation B
- BIOLOGICAL Formulation C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2020-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03572062
The ClinicalTrials.gov registry entry for NCT03572062 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03572062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03572062 about?
NCT03572062 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults". The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with seasonal inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine administered12 months after the initi...
What is the current status of trial NCT03572062?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2018-06-05. Estimated completion is 2020-08-19.
What interventions are being tested in trial NCT03572062?
The interventions under investigation include: Placebo (BIOLOGICAL), Formulation A (BIOLOGICAL), Formulation B (BIOLOGICAL), Formulation C (BIOLOGICAL).
Who is sponsoring clinical trial NCT03572062?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.